Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
1.180
+0.060 (5.36%)
Apr 2, 2025, 9:30 AM EST - Market open
Theriva Biologics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 11.61 | 23.18 | 41.79 | 67.33 | 6.23 | Upgrade
|
| Cash & Short-Term Investments | 11.61 | 23.18 | 41.79 | 67.33 | 6.23 | Upgrade
|
| Cash Growth | -49.91% | -44.53% | -37.93% | 981.18% | -58.61% | Upgrade
|
| Other Receivables | 3.32 | 1.94 | 0.23 | - | 0.47 | Upgrade
|
| Receivables | 3.32 | 1.94 | 0.23 | - | 0.47 | Upgrade
|
| Prepaid Expenses | 0.98 | 1.17 | 1.21 | 1.08 | 0.77 | Upgrade
|
| Other Current Assets | 0.37 | 1.12 | 2.29 | 0.46 | 0.47 | Upgrade
|
| Total Current Assets | 16.28 | 27.4 | 45.52 | 68.86 | 7.93 | Upgrade
|
| Property, Plant & Equipment | 1.54 | 2.18 | 1.54 | 1.48 | 0.45 | Upgrade
|
| Goodwill | - | 5.7 | 5.53 | - | - | Upgrade
|
| Long-Term Deferred Charges | 17.36 | 19.76 | 19.15 | - | - | Upgrade
|
| Other Long-Term Assets | 0.17 | 0.18 | 0.12 | 0.02 | 0.02 | Upgrade
|
| Total Assets | 35.35 | 55.22 | 71.86 | 70.37 | 8.41 | Upgrade
|
| Accounts Payable | 0.86 | 0.77 | 0.92 | 0.52 | 0.89 | Upgrade
|
| Accrued Expenses | 4.51 | 4.51 | 2.9 | 2.91 | 1.79 | Upgrade
|
| Current Portion of Long-Term Debt | 0.06 | 0.06 | 0.06 | - | - | Upgrade
|
| Current Portion of Leases | 0.54 | 0.49 | 0.22 | 0.12 | 0.29 | Upgrade
|
| Other Current Liabilities | 1.61 | 0.91 | 2.97 | - | - | Upgrade
|
| Total Current Liabilities | 7.59 | 6.74 | 7.06 | 3.55 | 2.97 | Upgrade
|
| Long-Term Debt | 0.09 | 0.16 | 0.22 | - | - | Upgrade
|
| Long-Term Leases | 0.87 | 1.44 | 1.19 | 1.4 | 0.19 | Upgrade
|
| Long-Term Deferred Tax Liabilities | - | - | 1.62 | - | - | Upgrade
|
| Other Long-Term Liabilities | 7.74 | 7.18 | 7.21 | - | - | Upgrade
|
| Total Liabilities | 16.29 | 15.52 | 17.3 | 4.96 | 3.15 | Upgrade
|
| Common Stock | 0 | 0 | 0.02 | 0.01 | 0.03 | Upgrade
|
| Additional Paid-In Capital | 355.5 | 346.54 | 343.75 | 336.68 | 240.82 | Upgrade
|
| Retained Earnings | -334.97 | -309.32 | -290.97 | -271.28 | -248.09 | Upgrade
|
| Treasury Stock | -0.29 | -0.29 | -0.29 | - | - | Upgrade
|
| Comprehensive Income & Other | -1.18 | 0.03 | -0.68 | - | - | Upgrade
|
| Total Common Equity | 19.07 | 36.96 | 51.83 | 65.41 | -7.24 | Upgrade
|
| Minority Interest | - | - | - | - | -2.77 | Upgrade
|
| Shareholders' Equity | 19.07 | 39.7 | 54.56 | 65.41 | 5.26 | Upgrade
|
| Total Liabilities & Equity | 35.35 | 55.22 | 71.86 | 70.37 | 8.41 | Upgrade
|
| Total Debt | 1.57 | 2.15 | 1.68 | 1.53 | 0.47 | Upgrade
|
| Net Cash (Debt) | 10.04 | 21.02 | 40.11 | 65.8 | 5.75 | Upgrade
|
| Net Cash Growth | -52.22% | -47.58% | -39.05% | 1043.52% | -59.83% | Upgrade
|
| Net Cash Per Share | 7.45 | 32.63 | 65.41 | 134.97 | 75.67 | Upgrade
|
| Filing Date Shares Outstanding | 2.78 | 0.69 | 0.6 | 0.63 | 0.52 | Upgrade
|
| Total Common Shares Outstanding | 2.78 | 0.69 | 0.6 | 0.53 | 0.12 | Upgrade
|
| Working Capital | 8.7 | 20.67 | 38.46 | 65.3 | 4.97 | Upgrade
|
| Book Value Per Share | 6.85 | 53.89 | 85.67 | 123.84 | -61.91 | Upgrade
|
| Tangible Book Value | 19.07 | 31.26 | 46.31 | 65.41 | -7.24 | Upgrade
|
| Tangible Book Value Per Share | 6.85 | 45.58 | 76.54 | 123.84 | -61.91 | Upgrade
|
| Machinery | 0.71 | 0.9 | 0.9 | 0.83 | 0.81 | Upgrade
|
| Leasehold Improvements | 0.09 | 0.09 | 0.09 | 0.09 | 0.44 | Upgrade
|
Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.